Vertex Pharmaceuticals (VRTX) Change in Accured Expenses (2009 - 2026)

Vertex Pharmaceuticals' Change in Accured Expenses history runs 18 years deep, the most recent figure standing at $23.1 million for Q1 2026.

• On a quarterly basis, Change in Accured Expenses fell 51.98% year-over-year to $23.1 million in Q1 2026; TTM through Mar 2026 was -$141.9 million, a 77.82% decrease from a year earlier, with the FY2025 full-year figure at -$116.9 million, down 394.46% from the prior year.
• Change in Accured Expenses climbed to $23.1 million in Q1 2026 per VRTX's latest filing, from -$159.6 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $668.3 million in Q3 2023 and bottomed at -$587.8 million in Q3 2022.
• The 5-year median for Change in Accured Expenses is $61.6 million (2022), against an average of $41.0 million.
• Biggest YoY gain for Change in Accured Expenses was 994.11% in 2022; the steepest drop was 2659.62% in 2022.
• Year by year, Change in Accured Expenses stood at $583.2 million in 2022, then plunged by 198.97% to -$577.2 million in 2023, then rose by 14.54% to -$493.3 million in 2024, then soared by 67.65% to -$159.6 million in 2025, then soared by 114.47% to $23.1 million in 2026.
• Per Business Quant, the three latest VRTX Change in Accured Expenses figures stand at $23.1 million (Q1 2026), -$159.6 million (Q4 2025), and -$172.0 million (Q3 2025).